Log In Sign up
The largest database of trusted experimental protocols

4 hydroxytamoxifen 4 oht h7904

Manufactured by Merck Group
Visit Supplier
Sourced in United States

4-hydroxytamoxifen (4-OHT) (H7904) is a selective estrogen receptor modulator (SERM) compound commonly used in cell-based research. It acts as an antagonist on estrogen receptors. 4-OHT is a metabolite of the drug tamoxifen and is commonly used as a tool compound in studies involving the estrogen signaling pathway.

Automatically generated - may contain errors

Lab products found in correlation

Encorafenib, by Novartis (2 mentions) Dabrafenib, by GlaxoSmithKline (2 mentions) Hygromycin, by Thermo Fisher Scientific (2 mentions) Vemurafenib, by Plexxikon (2 mentions) Tak 632, by Selleck Chemicals (2 mentions) Doxycycline d3072, by Merck Group (2 mentions) Plx8394, by Plexxikon (2 mentions) Ly3009120, by Active Motif (2 mentions) Lapatinib, by GlaxoSmithKline (2 mentions) β estradiol e2 e8875, by Merck Group (1 mentions)

4 protocols using 4 hydroxytamoxifen 4 oht h7904

1

Apigenin, Tamoxifen, and Estradiol Protocols

Check if the same lab product or an alternative is used in the 5 most similar protocols
Apigenin (Api) (A3145) ≥97% (TLC) from parsley, 4-hydroxytamoxifen (4-OHT) (H7904) ≥98% Z isomer, and β-estradiol (E2) (E8875) ≥98% were purchased from Sigma-Aldrich (St Louis, MO, USA).
Pham T.H., Page Y.L., Percevault F., Ferrière F., Flouriot G, & Pakdel F. (2021). Apigenin, a Partial Antagonist of the Estrogen Receptor (ER), Inhibits ER-Positive Breast Cancer Cell Proliferation through Akt/FOXM1 Signaling. International Journal of Molecular Sciences, 22(1), 470.
+ Open protocol
+ Expand
2

Comprehensive Drug Treatment Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
BGB659 was obtained from Beigene. Vemurafenib and PLX8394 were from Plexxikon. Lapatinib and dabrafenib were from GlaxoSmithKline. TAK632 was from Selleckchem. encorafenib was from Novartis. LY3009120 was purchased from Active Biochem, All these drugs were dissolved in DMSO to yield 10mM stock and stored at −20 °C Doxycycline (D3072) and 4-hydroxytamoxifen (4-OHT) (H7904) were purchased from Sigma Aldrich, Puromycin (A1113802) and Hygromycin (10687010) stock solution was from Thermo Fisher Scientific.
Yao Z., Gao Y., Su W., Yaeger R., Tao J., Na N., Zhang Y., Zhang C., Rymar A., Tao A., Timaul N.M., Mcgriskin R., Outmezguine N.A., Zhao H., Chang Q., Qeriqi B., Barbacid M., de Stanchina E., Hyman D.M., Bollag G, & Rosen N. (2018). RAF inhibitor PLX8394 selectively disrupts BRAF-dimers and RAS-independent BRAF mutant-driven signaling. Nature medicine, 25(2), 284-291.
+ Open protocol
+ Expand
3

Conditional Lineage Tracing in Mice

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Cdh5-CreERT2 (Wang et al, 2010 (link)) and Ai14 (R26-tdTom) (Madisen et al, 2010 (link)) mice described previously were analyzed on a C57BL/6J background. The morning of vaginal plug detection was considered as embryonic day 0 (E0). For inducing recombination during embryonic development, a single dose of 1 mg of 4-hydroxytamoxifen (4-OHT, H7904; Sigma-Aldrich, ≥98% Z [trans] isomer) or tamoxifen (tam, T5648; Sigma-Aldrich) dissolved in peanut oil (10 mg/ml) was administered intraperitoneally to pregnant females at a defined developmental stage as indicated in the figures and figure legends. All experimental procedures were approved by the Uppsala Animal Experiment Ethics Board (permit numbers 130/15 and 5.8.18-06383/2020) and performed in compliance with all relevant Swedish regulations.
Zhang Y., Ortsäter H., Martinez-Corral I, & Mäkinen T. (2022). Cdh5-lineage–independent origin of dermal lymphatics shown by temporally restricted lineage tracing. Life Science Alliance, 5(11), e202201561.
+ Open protocol
+ Expand
4

Comprehensive Drug Treatment Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
BGB659 was obtained from Beigene. Vemurafenib and PLX8394 were from Plexxikon. Lapatinib and dabrafenib were from GlaxoSmithKline. TAK632 was from Selleckchem. encorafenib was from Novartis. LY3009120 was purchased from Active Biochem, All these drugs were dissolved in DMSO to yield 10mM stock and stored at −20 °C Doxycycline (D3072) and 4-hydroxytamoxifen (4-OHT) (H7904) were purchased from Sigma Aldrich, Puromycin (A1113802) and Hygromycin (10687010) stock solution was from Thermo Fisher Scientific.
Yao Z., Gao Y., Su W., Yaeger R., Tao J., Na N., Zhang Y., Zhang C., Rymar A., Tao A., Timaul N.M., Mcgriskin R., Outmezguine N.A., Zhao H., Chang Q., Qeriqi B., Barbacid M., de Stanchina E., Hyman D.M., Bollag G, & Rosen N. (2018). RAF inhibitor PLX8394 selectively disrupts BRAF-dimers and RAS-independent BRAF mutant-driven signaling. Nature medicine, 25(2), 284-291.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!